Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma

被引:30
作者
Coudore, Francois [1 ,3 ]
Roche, Denis [1 ]
Lefeuvre, Sandrine [2 ]
Faussot, Delphine [1 ]
Billaud, Eliane M. [2 ,4 ]
Loriot, Marie-Anne [1 ,4 ]
Beaune, Philippe [1 ,4 ]
机构
[1] Hop Europeen Georges Pompidou, AP HP, Dept Biochem, F-75015 Paris, France
[2] Hop Europeen Georges Pompidou, AP HP, Dept Pharmacol, F-75015 Paris, France
[3] Univ Paris 11, Fac Pharm, F-92296 Chatenay Malabry, France
[4] Paris Descartes Univ, Fac Med, F-75006 Paris, France
关键词
DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; ENDOGENOUS URACIL; SEVERE TOXICITY; 5-FLUOROURACIL; DIHYDROURACIL; HPLC; ASSAY; FLUOROPYRIMIDINES; FLUOROURACIL; CHEMOTHERAPY;
D O I
10.1093/chromsci/bms085
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, rapid, sensitive and specific ultra-high-performance liquid chromatography tandem mass spectrometry method (Waters UPLC-MS-MS) is developed and validated for the quantification of uracil (U) and 5,6-dihydrouracil (UH2) levels in human plasma. Analytes are extracted using ethyl acetate and isopropanol after deproteination, and separated by high-performance liquid chromatography (HPLC) (Acquity UPLC BEH C18 column) in a binary mobile phase system under gradient elution conditions at a flow rate of 0.4 mL/min. 5-Bromo-uracil (UBr) is used as the internal standard. The detection is performed on a triple-quadrupole mass spectrometer via electrospray positive ionization. Multiple reaction monitoring mode using the transitions m/z 112.82 -> 70.05, m/z 114.88 -> 55.04 and m/z 190.83 -> 117.86 is used to quantify U, UH2 and UBr, respectively. The method is linear in the concentration range of 0.625-160.0 ng/mL. The total run time is 4.5 min per injection. Nine-point calibration curve and four-points quality controls are used. Excellent linearity and precision are observed with correlation coefficient (r(2)) > 0.9999. The intra-batch and inter-batch precisions are <= 7.3% and <= 8.6%, and accuracy is <= 17%. The developed method is shown to be suitable for routine quantitative determination of U, UH2 and 5,6-dihydrouracil-to-uracil ratio in clinical practice.
引用
收藏
页码:877 / 884
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 2013, Guidance for industry, bioanalytical method validation
[2]   5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency [J].
Boisdron-Celle, M. ;
Remaud, G. ;
Traore, S. ;
Poirier, A. L. ;
Gamelin, L. ;
Morel, A. ;
Gamelin, E. .
CANCER LETTERS, 2007, 249 (02) :271-282
[3]  
Bonfiglio R, 1999, RAPID COMMUN MASS SP, V13, P1175, DOI 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO
[4]  
2-0
[5]   Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses [J].
Chambers, Erin ;
Wagrowski-Diehl, Diane M. ;
Lu, Ziling ;
Mazzeo, Jeffrey R. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 852 (1-2) :22-34
[6]   A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity [J].
Ciccolini, J ;
Mercier, C ;
Blachon, MF ;
Favre, R ;
Durand, A ;
Lacarelle, B .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (04) :307-315
[7]   A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy [J].
Ciccolini, Joseph ;
Mercier, Cedric ;
Evrard, Alexandre ;
Boyer, Jean-Christophe ;
Duffaud, Florence ;
Dahan, Laetitia ;
Richard, Karine ;
Blanquicett, Carmelo ;
Milano, Gerard ;
Blesius, Aurore ;
Durand, Alain ;
Seitz, Jean-Francois ;
Favre, Roger ;
Lacarelle, Bruno .
THERAPEUTIC DRUG MONITORING, 2006, 28 (05) :678-685
[8]   High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma [J].
Déporte, R ;
Amiand, M ;
Moreau, A ;
Charbonnel, C ;
Campion, L .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 834 (1-2) :170-177
[9]   Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients [J].
Di Paolo, A ;
Danesi, R ;
Falcone, A ;
Cionini, L ;
Vannozzi, F ;
Masi, G ;
Allegrini, G ;
Mini, E ;
Bocci, G ;
Conte, PF ;
Del Tacca, M .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1301-1306
[10]   Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer [J].
Gamelin, Erick ;
Delva, Remy ;
Jacob, Jacques ;
Merrouche, Yacine ;
Raoul, Jean Luc ;
Pezet, Denis ;
Dorval, Etienne ;
Piot, Gilles ;
Morel, Alain ;
Boisdron-Celle, Michele .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2099-2105